<DOC>
	<DOCNO>NCT02218203</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind 4x4 factorial crossover clinical trial part large NIH-funded study evaluate analgesic efficacy multiple dose-combinations chronic oral ( PO ) dextromethorphan intravenous ( IV ) lidocaine central neuropathic pain follow spinal cord injury .</brief_summary>
	<brief_title>Clinical Neuropharmacology Pain Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>1 . Healthy male female adult , age 18 70 central neuropathic pain minimum 3 month follow SCI confirm neurologic evaluation , average pain intensity score least moderate least 50 % day 7 day prior screen visit 7 day prior start study medication . 2 . Subjects use medication stabilize medication regimen chronic wellcontrolled medical condition 3 . Serum laboratory examination obtain study entry : Liver function test ( albumin within 20 % normal , SGOT/SGPT within 50 % normal ) . For woman childbearing age : negative serum beta HCG . 4 . Postmenopausal woman , physically incapable childbearing , practice acceptable method birth control . 5 . Normal cognitive function . 6 . Normal communicative ability ( English ) . 7 . Ability demonstrate competence record five time daily pain diary 1 week ( 100 % compliance ) , complete require questionnaire . 8 . Signed informed consent . 1 . Pregnancy breastfeed . 2 . Renal hepatic dysfunction . 3 . Significant cardiac disease ( e.g . MI within 1 year ) . 4 . Signs symptoms central neurological disorder , exclude SCI . 5 . Severe psychological disorder require treatment . 6 . Concurrent use monoamine oxidase inhibitor within 2 week prior study entry . 7 . Use know CYP2D6 ( CYP3A4 ) inhibitors inducer . 8 . History hypersensitivity intolerance dextromethorphan lidocaine . 9 . Chronic substance abuse , include alcohol . 10 . Participation study investigational drug device within 30 day prior screen study . 11 . Poor metabolizer P450 2D6 substrate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>chronic pain</keyword>
	<keyword>central neuropathic pain</keyword>
	<keyword>spinal cord injury</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>lidocaine</keyword>
	<keyword>combination therapy</keyword>
	<keyword>analgesia</keyword>
</DOC>